
Shares of drug developer Lexeo Therapeutics LXEO.O rise 2% to $7.63 premarket
Co says it named cardiologist Dr. Narinder Bhalla as chief medical officer
Co says its research head Dr. Eric Adler will become CEO of Myoventive, which focuses on RNA-based treatments for inherited heart conditions
CTO José Manuel Otero moves to the chief operating officer's role; co also hires two VPs to lead early- and late-stage cardiology programs - LXEO
Shares up ~51% in 2025